BLA 125522 · Amgen INC
Repatha
Evolocumab · Injection · PCSK9 Inhibitor
OrphanLast checked: Nov 20, 2026Latest source record: Oct 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Feb 26, 2021
Approved uses
7
Original approval plus efficacy supplements
Registered trials
135
43 Phase 3, 12 recruiting
FAERS reports
165,049
28,672 serious, 2,144 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 12, 2026.
REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, coronary revascularization, or any ischemia-driven arterial revascularization) in adults at increased risk for these events. As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). REPATHA is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, coronary revascularization, or any ischemia-driven arterial revascularization) in adults at increased risk for these events. ( 1 ) As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in ( 1 ): adults with hypercholesterolemia. adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).
Mechanism: Evolocumab is a human monoclonal IgG2 directed against human proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 9, 2026 Supplement 47 · Efficacy OrphanLabelLetter
- Sep 24, 2021 Supplement 29 · Efficacy LabelLetter
- Feb 26, 2021 Original approval · Efficacy OrphanLabelLetterReview
- Dec 1, 2017 Supplement 13 · Efficacy · priority review LabelLetter
- Dec 1, 2017 Supplement 14 · Efficacy LetterLabel
- Jul 8, 2016 Supplement 1 · Efficacy OrphanReviewLetter
- Aug 27, 2015 Original approval · Type 1 - New Molecular Entity OrphanLabelSummary ReviewReview
1 products under this application
- REPATHA · EVOLOCUMAB 140MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Evolocumab" as an intervention, any sponsor and status, largest first.
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated RiskPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01764633 · 27,564 participants · Start Feb 8, 2013 · Primary completion Nov 11, 2016
Drug: Evolocumab; Placebo · For: Dyslipidemia
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,284 sites in all
- Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokePivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT03872401 · 12,301 participants · Start Jun 11, 2019 · Primary completion Jul 25, 2025
Drug: Evolocumab; Placebo · For: Coronary Heart Disease (CHD)
Sites: Athens, Alabama; Birmingham, Alabama; Huntsville, Alabama · 852 sites in all
- EVOLVE-MI: EVOLocumab Very Early After Myocardial InfarctionPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT05284747 · 6,019 participants · Start Oct 26, 2022 · Primary completion May 29, 2027
Drug: Evolocumab; Routine Lipid Management · For: Cardiovascular Disease; Myocardial Infarction; Stroke and 1 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Huntsville, Alabama · 120 sites in all
- Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label ExtensionPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT02867813 · 5,035 participants · Start Sep 2, 2016 · Primary completion Mar 21, 2022
Drug: Evolocumab · For: Dyslipidemia
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 198 sites in all
- Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed DyslipidemiaPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01854918 · 3,681 participants · Start Apr 23, 2013 · Primary completion May 31, 2018
Drug: Evolocumab; Standard of Care · For: Hyperlipidemia and Mixed Dyslipidemia
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 363 sites in all
- Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCIPivotal-lookingActive, not recruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT04951856 · 2,166 participants (planned) · Start Sep 29, 2021 · Primary completion May 22, 2026
Drug: Evolocumab 140 MG/ML; Standard of care (SOC) · For: STEMI - ST Elevation Myocardial Infarction; NSTEMI - Non-ST Segment Elevation MI
Sites: Paris, France
- LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2Pivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01763866 · 2,067 participants · Start Jan 15, 2013 · Primary completion Nov 12, 2013
Drug: Evolocumab; Ezetimibe and 5 more · For: Hyperlipidemia
Sites: Birmingham, Alabama; Glendale, Arizona; Tucson, Arizona · 244 sites in all
- Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk SubjectsPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT02207634 · 1,974 participants · Start Sep 10, 2014 · Primary completion Nov 11, 2016
Drug: Evolocumab; Placebo and 1 more · For: Dyslipidemia
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 416 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device difficult to use33,254
- drug dose omission by device24,856
- wrong technique in product usage process22,690
- accidental exposure to product17,173
- injection site pain11,254
- product storage error6,709
- back pain5,658
- myalgia5,484
- injection site bruising4,954
- drug dose omission4,929
- device use error4,408
- fatigue4,161
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 13 |
| 2015 | 801 |
| 2016 | 6,377 |
| 2017 | 20,201 |
| 2018 | 28,249 |
| 2019 | 9,722 |
| 2020 | 8,999 |
| 2021 | 10,476 |
| 2022 | 12,351 |
| 2023 | 24,562 |
| 2024 | 25,531 |
| 2025 | 7,912 |
| 2026 | 9,852 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Sabatine MS, Giugliano RP, Keech AC, et al. · N Engl J Med 2017 · Multicenter Study, Randomized Controlled Trial
- Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.
Bohula EA, Marston NA, Bhatia AK, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
O'Donoghue ML, Giugliano RP, Wiviott SD, et al. · Circulation 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
O'Donoghue ML, Fazio S, Giugliano RP, et al. · Circulation 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ, Puri R, Anderson T, et al. · JAMA 2016 · Multicenter Study, Randomized Controlled Trial
- Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
Nicholls SJ, Kataoka Y, Nissen SE, et al. · JACC Cardiovasc Imaging 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Amgen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.